Results 211 to 220 of about 1,885,895 (335)

Targeted Lysosomal Degradation of Extracellular and Membrane Proteins: From Receptor Hijacking to Programmable Endolysosomal Routing

Advanced Science, EarlyView.
Targeted chimeric degraders engage extracellular or membrane proteins and endocytosable cell‐surface receptors, forming ternary complexes that induce receptor‐mediated internalization. Following endocytosis, post‐endocytic sorting—not internalization alone—determines target fate.
Ke Liu, Xiyan Wang, Xiaozhen Liu, Chaoqi He, Da Qian, Xuli Meng, Liquan Zhu   +6 more
wiley   +1 more source

Breaking barriers: nanosystems to overcome solubility and permeability challenges of second-generation tyrosine kinase inhibitors. [PDF]

Beilstein J Nanotechnol
Shree B, Sharma A, Kumar M, Chawla R, Mishra B.   +4 more
europepmc   +1 more source

Biomimetic Scaffold‐Based 3D Models for Decoding Cancer Biology and Advancing Therapy

Advanced Science, EarlyView.
A timeline of the research history of 3D biomimetic scaffold materials and platforms. With advances in biomimetic materials and 3D scaffold technologies, their functional scope has expanded from mimicking basic physical and biochemical properties to increasingly replicating complex pathophysiological processes.
Haitao Zhao, Yuechen Han, Jie Li, Peng Luo, Lin Qi, Zhiwei Xia, Xiaosong Li, Quan Cheng, Chenshen Huang, Wantao Wu, Hao Zhang   +10 more
wiley   +1 more source

Farnesyl Transferase Inhibitor KO-2806 (Darlifarnib) Enhances the Antitumor Activity of Tyrosine Kinase Inhibitors in RCC. [PDF]

Mol Cancer Ther
Gasendo JG, Chan S, Patel HV, Smith AE, Kessler L, Liu YA, Mitra A, Burrows F, Malik S.   +8 more
europepmc   +1 more source

Structural Basis of Lymphangiogenic Receptor VEGFR‐3 Activation Mediated by Distinctive Clustering of the Ligand–Receptor Complex

Advanced Science, EarlyView.
VEGF‐C and its receptor VEGFR‐3 are critical for lymphangiogenesis. Cryo‐EM structures of the VEGFR‐3/VEGF‐C ectodomain complex reveal a canonical 2:2 ligand–receptor hetero‐tetramer that further assembles into higher‐order clusters beyond simple receptor dimerization.
Ryeongeun Cho, Jinsook Ahn, Jimin Yang, Dong Sun Lee, Gahi Hong, Sangkyu Lee, Ho Min Kim   +6 more
wiley   +1 more source

Treatment response and survival outcomes with BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: a retrospective study. [PDF]

Front Med (Lausanne)
Liu Y, Zhang L, Zeng L.
europepmc   +1 more source

Beyond Conventional: A Review of Phytochemical‐Hydrogel Systems Enhanced by AI and 3D Printing for Chronic Wound Management

Advanced Science, EarlyView.
This review systematically bridges chronic wound pathology with natural phytochemical hydrogel therapeutics. A pathology‐to‐phytochemical mechanistic mapping framework is established, linking specific wound hallmarks to targeted phytochemical interventions.
Yitao Zhou, Xing Liu, Cuiyi Wang, Xiaoxuan Zhao, Pengrun Zhang, Jingjing Gu, Qiuhua Sun, Malcolm Xing, Yeqin Yang   +8 more
wiley   +1 more source

Comparison of variably specific Bruton tyrosine kinase inhibitors on platelet aggregation mediated by Fcγ receptor (FcγR) IIa, glycoprotein VI, and platelet endothelial aggregation receptor (PEAR) 1: implications for Bruton tyrosine kinase inhibitors as antithrombotic therapy. [PDF]

Res Pract Thromb Haemost
Kartika T, Buitrago L, Li J, Cunningham-Rundles C, Coller BS.   +4 more
europepmc   +1 more source

PTBP1‐Mediated Alternative Splicing of DNAJB6 Promotes Everolimus Resistance in Clear Cell Renal Cell Carcinoma via EIF4B/PKIB/AKT/mTOR Positive Feedback Loop

Advanced Science, EarlyView.
PTBP1‐mediated alternative splicing drives a pathogenic switch to the DNAJB6b isoform in everolimus‐resistant clear cell renal cell carcinoma. This splicing event programs a positive feedback loop including EIF4B/PKIB/AKT/mTOR, promoting aggressive therapy resistance.
Xiu‐wu Pan, Hong‐feng Zheng, Mu‐chen Li, Jia‐lin Zhou, Hang‐biao Zhang, Dong‐hao Lyu, Yi‐fan Tang, Tian‐yue Yang, Yi‐fan Liu, Zi‐chang Liu, Wen‐jie Ma, Yuan‐bo Zong, Jian‐gui Liu, Zi‐xuan Gong, Hao Zhang, Ke‐qin Dong, Wang Zhou, Jian‐qin Ye, Xin‐gang Cui   +18 more
wiley   +1 more source

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL. [PDF]

Oncol Ther
Ermann DA, Stephens DM, Wang X, Varghese I, De Souza H, Sheetz C, Fu Q, Maglinte GA, Williams R, Seymour EK, van Beuge D, Shadman M, Jacobs R.   +12 more
europepmc   +1 more source